^Sup 90^Y-Labeled mAb in Ovarian Cancer

By Anonymous

In a study published in the June 15 issue of the International Journal of Cancer (2007;120:2710-2714), Oei et al. from the Radboud University Nijmegen Medical Centre (The Netherlands) reported on a study analyzing the sites and patterns of disease recurrence in patients with epithelial ovarian cancer to assess the influence of a single intraperitoneal administration of ^sup 90^Y-labeled murine monoclonal antibody (mAb). The study included 447 patients in a phase III trial who were in complete clinical remission with FIGO stage Ic-IV ovarian cancer and who were randomized to standard treatment plus a single intraperitoneal administration of ^sup 90^Y- labeled mAb (224 patients) or to standard treatment alone after negative second-look laparoscopy (223 patients). Patients were followed for a methan of 3.5 years. Relapse/recurrence was noted in 104 of the ^sup 90^Y-labeled mAb group and in 98 of the control arm, with significantly fewer intraperitoneal and more extraperitoneal relapses occurring in the radioimmunotherapy arm. The time to intraperitoneal recurrence was significantly longer and time to extraperitoneal recurrence was significantly shorter for the ^sup 90^Y-labeled mAb group. These and other data led the authors to conclude that no survival benefit accrued to this intraperitoneal radioimmunotherapy as consolidation treatment for epithelial ovarian cancer and that improved control of intraperitoneal disease was offset by increased extraperitoneal recurrences. International Journal of Cancer

Copyright Society of Nuclear Medicine Aug 2007

(c) 2007 Journal of Nuclear Medicine, The. Provided by ProQuest Information and Learning. All rights Reserved.